Global pharma major Lupin Limited (Lupin) today announced the launch of Turqoz® (Norgestrel and Ethinyl Estradiol) Tablets USP,0.3 mg/0.03 mg, after having received an approval from the United States Food and Drug Administration (U.S. FDA).
Turqoz® (Norgestrel and Ethinyl Estradiol) Tablets USP,0.3 mg/0.03 mgis the generic equivalent of Lo/Ovral-28(Norgestrel and Ethinyl Estradiol) Tablets,0.3 mg/0.03 mg of Wyeth Pharmaceuticals LLC andis a contraceptive drug indicated to prevent pregnancy.
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of USD 33million in the U.S. (IQVIA MAT October 2023).
About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Source : Lupin
